Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 4 art units • 4 examiners • 0 of 5 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Charité-Universitätsmedizin Berlin has 1 pending office action in Biotechnology & Pharmaceuticals. The matter involves 1 distinct examiner and 1 distinct art unit, producing a focused prosecution profile.
JUEDES, AMY E is the busiest examiner, with 1 pending matter. Preparation can center on the examiner’s objections and the examination practices applicable to the assigned art unit.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (20%) |
| §103 only | 1 (20%) |
| §102 only | 1 (20%) |
| Multi-statute (no §101) | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ZARA, JANE J | 2 | 71.0% | +16.1% |
| JUEDES, AMY E | 1 | 44.7% | +41.9% |
| GIAMMONA, FRANCESCA FILIPPA | 1 | 37.3% | +58.8% |
| GROSS, CHRISTOPHER M | 1 | 63.5% | +40.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17422093 | A METHOD FOR DETERMINING THE SEVERITY OR GRADE OF HUMAN PAPILLOMAVIRUS (HPV)-INDUCED DYSPLASIA | GIAMMONA, FRANCESCA FILIPPA | 27d |
| 18268906 | REPROGRAMMING IMMUNE CELLS BY TARGETED INTEGRATION OF ZETA-DEFICIENT CHIMERIC ANTIGEN RECEPTOR TRANSGENES | ZARA, JANE J | — |
| 18042550 | A CHIMERIC ANTIGEN RECEPTOR CONSTRUCT ENCODING A CHECKPOINT INHIBITORY MOLECULE AND AN IMMUNE STIMULATORY CYTOKINE AND CAR-EXPRESSING CELLS RECOGNIZING CD44v6 | JUEDES, AMY E | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17422093 | A METHOD FOR DETERMINING THE SEVERITY OR GRADE OF HUMAN PAPILLOMAVIRUS (HPV)-INDUCED DYSPLASIA | GIAMMONA, FRANCESCA FILIPPA | 27d |
| 17297944 | METHOD FOR PREDICTING THE RESPONSE TO CANCER IMMUNOTHERAPY IN CANCER PATIENTS | GROSS, CHRISTOPHER M | 29d |
| 18264676 | COMPOSITION AND METHOD FOR REDUCING OXALATE LEVELS IN PATIENTS RECEIVING MAINTENANCE DIALYSIS | ZARA, JANE J | — |
| 18268906 | REPROGRAMMING IMMUNE CELLS BY TARGETED INTEGRATION OF ZETA-DEFICIENT CHIMERIC ANTIGEN RECEPTOR TRANSGENES | ZARA, JANE J | — |
| 18042550 | A CHIMERIC ANTIGEN RECEPTOR CONSTRUCT ENCODING A CHECKPOINT INHIBITORY MOLECULE AND AN IMMUNE STIMULATORY CYTOKINE AND CAR-EXPRESSING CELLS RECOGNIZING CD44v6 | JUEDES, AMY E | — |
| Art Unit | Apps |
|---|---|
| 1637 | 2 |
| 1644 | 1 |
| 1681 | 1 |
| 1684 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18264676 | COMPOSITION AND METHOD FOR REDUCING OXALATE LEVELS IN PATIENTS RECEIVING MAINTENANCE DIALYSIS | ZARA, JANE J | 1637 | §103 | Non-Final OA | — | Pending | Aug 08, 2023 |
| 18268906 | REPROGRAMMING IMMUNE CELLS BY TARGETED INTEGRATION OF ZETA-DEFICIENT CHIMERIC ANTIGEN RECEPTOR TRANSGENES | ZARA, JANE J | 1637 | §101§102§103§112 | Non-Final OA | — | Pending | Jun 21, 2023 |
| 18042550 | A CHIMERIC ANTIGEN RECEPTOR CONSTRUCT ENCODING A CHECKPOINT INHIBITORY MOLECULE AND AN IMMUNE STIMULATORY CYTOKINE AND CAR-EXPRESSING CELLS RECOGNIZING CD44v6 | JUEDES, AMY E | 1644 | §103§112 | Final Rejection | — | Pending | Feb 22, 2023 |
| 17422093 | A METHOD FOR DETERMINING THE SEVERITY OR GRADE OF HUMAN PAPILLOMAVIRUS (HPV)-INDUCED DYSPLASIA | GIAMMONA, FRANCESCA FILIPPA | 1681 | §103§112 | Final Rejection | 27d | Pending | Jul 09, 2021 |
| 17297944 | METHOD FOR PREDICTING THE RESPONSE TO CANCER IMMUNOTHERAPY IN CANCER PATIENTS | GROSS, CHRISTOPHER M | 1684 | §102 | Final Rejection | 29d | Pending | May 27, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCharité - Universitätsmedizin Berlin has 5 pending office actions as of October 2026, spread across 4 art units and 4 examiners.
Jane J Zara has the most, with 2 of Charité - Universitätsmedizin Berlin's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
